The RACE-3 is on: Double-locking sinus rhythm by upstream and downstream therapy
Pavlovic, Davor; Kirchhof, Paulus; Fabritz, Larissa

DOI: 10.1093/eurheartj/ehy018
License: Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.
The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy

Davor Pavlovic¹, Paulus Kirchhof¹,²,³, and Larissa Fabritz¹,³*

¹Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; ²Sandwell and West Birmingham NHS Trust, Birmingham, UK; and ³University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.

This editorial refers to ‘Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial’, by M. Rienenstra et al. doi:10.1093/eurheartj/ehx739.

Recent advances in the field of anticoagulation have given us powerful tools to reduce stroke and its associated disease burden in patients with atrial fibrillation.¹⁻⁴ More work needs to be done to offer adequate anticoagulation to all patients with atrial fibrillation at risk for stroke,¹⁵ and ongoing trials explore the limits of anticoagulation in patients with very low levels of atrial arrhythmias.⁷,⁸ However, even in adequately anticoagulated patients with atrial fibrillation, important unmet therapeutic needs remain, particularly around prevention of sudden death, heart failure, and unplanned cardiovascular hospitalizations.⁵

Many groups have speculated that ‘upstream therapy’ or ‘prevention of atrial remodelling’ can improve rhythm control therapy in patients with atrial fibrillation.⁷,¹⁰ Clinical trials conducted so far have not conclusively demonstrated effectiveness of either angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), or statins in reducing recurrent AF.¹¹⁻¹³ In this issue of the journal, van Gelder and colleagues report the outcome of the RACE-3 study.¹⁴ RACE-3 tested whether the addition of a comprehensive ‘upstream therapy’ package, consisting of mineralocorticoid receptor antagonists (MRAs), statins, ACE-Is and/or ARBs, and cardiac rehabilitation including physical activity, dietary restrictions, and counselling, improves sinus rhythm maintenance in anticoagulated patients with persistent atrial fibrillation undergoing rhythm control therapy.⁵ This elegant design combines several important components of ‘upstream therapy’ into a single intervention, thus quantifying the positive effect of ‘upstream therapy’ in its totality for recurrent atrial fibrillation in 1 year.¹⁵

In RACE-3, patients randomized to the ‘upstream therapy’ intervention had lower blood lipids levels, lower levels of brain natriuretic peptide (BNP), and lower blood pressure than the control group at follow up, demonstrating that the intervention had the desired biological effects. The feasibility of an intervention to reduce the cardiovascular risk profile in patients with atrial fibrillation is an important finding in itself and should empower primary and secondary prevention initiatives. The authors found a slightly higher number of patients in sinus rhythm after 1 year, with a nominally significant P-value (P = 0.04) in the primary outcome of the study, defined as sinus rhythm on at least 6 out of 7 days of a 7 day Holter ECG at 1 year follow-up. Other rhythm outcomes were not different between groups, e.g. the number of repeat cardioversions, the time to recurrent atrial fibrillation, or cardiovascular hospitalizations. This may be due to the weaker long-term and indirect effects of the intervention on atrial electrical function (Take home figure) which contrasts with the immediate direct effects of anti-arrhythmic drugs and ablation procedures. Of note, the use of ACE-Is/ARBs was high in both study groups, and catheter ablation was rarely used in the study population, with only seven ablations performed.

The results illustrate two main points: (i) a comprehensive ‘upstream therapy’ treatment package in patients with persistent atrial fibrillation and some degree of heart failure only slightly improves prevention of recurrent AF in the short term; and (ii) such treatment seems safe and leads to desirable reductions in lipid profiles, BNP, and blood pressure.

What does the study add?

Like every well-designed study, RACE-3 provides important answers and raises new questions. MRAs, statins, ACE-Is/ARBs, and cardiac rehabilitation improved important surrogates for cardiovascular outcomes without major safety concerns. As such, the study results demonstrate the feasibility of comprehensive cardiovascular risk reduction in patients with atrial fibrillation, supporting the concept of integrated care for these patients.¹⁵,⁶ as the authors discuss elegantly.¹⁴ RACE-3 also illustrates the limited short-term effectiveness of ‘upstream therapy’ for preventing recurrent atrial fibrillation after cardioversion: even a comprehensive package tackling underlying cardiovascular conditions by rehabilitation, statins, MRAs, and renin-
angiotensin–aldosterone system (RAAS) inhibition did not affect the number of repeat cardioversions, time to recurrent atrial fibrillation, or cardiovascular hospitalizations. More efficient weight loss strategies could possibly also lead to better outcomes in the future, as there was only a slight decrease in body mass index in the intervention group in RACE-3. Longer term assessment of the intervention tested in RACE-3 may provide further benefits to the patients as the ‘upstream therapy’ package may have more pronounced effects on atrial fibrillation after several years of treatment. We look ahead for the long-term follow-up of this patient cohort for answers to these questions.

What does that mean for clinical practice?

MRA inhibition, RAAS inhibition, and statins should be considered in patients with persistent atrial fibrillation as part of an integrated approach to the care of patients with atrial fibrillation. The results also illustrate that the effect of ‘upstream therapy’ on recurrent atrial fibrillation in patients with persistent atrial fibrillation is modest at best, and clearly weaker than the short-term effect of antiarrhythmic drugs. Treatment approaches based on the major drivers of atrial fibrillation (Take home figure).

More upstream and downstream work is needed

The results of RACE-3 illustrate that risk factor management cannot replace direct treatment of the electrical drivers of atrial fibrillation by antiarrhythmic drugs and catheter ablation (Take home figure). While we await the full publication of the CASTLE-AF trial outcome, the next few years should provide new information on the role of modern and comprehensive rhythm control therapy for cardiovascular outcomes in patients with atrial fibrillation. In addition, there is a clear need to improve heart failure treatment by antiarrhythmic drugs and catheter ablation. Clearly, the road to successful maintenance of sinus rhythm requires careful consideration of the major health modifiers causing atrial fibrillation. A substantial body of evidence demonstrates that atrial fibrillation and other underlying cardiovascular conditions alter structural and electrical properties of the atria, including interstitial fibrosis, increased formation of extracellular matrix, alterations in cell–cell contact proteins, adipose tissue activation and infiltration, changes in gene expression pattern, oxidative stress, calcium abnormalities, and others. Dysregulation of the RAAS and autonomic dysfunction are found in atrial fibrillation, hypertension, heart failure,
kidney dysfunction, or obesity, and further promote atrial remodelling. Early-onset atrial fibrillation in particular can be driven by a genetic or genomic component that must also be taken into consideration during treatment. Attenuation of such complex pathophysiological stimuli requires a collaborative effort of basic and clinical arms of our research, if we are to tackle the ever-increasing incidence and prevalence of atrial fibrillation.

The double lock
Joint upstream and downstream therapy can provide a double lock to slow progression of the atrial fibrillation, but more work needs to be done. The results of RACE-3 thus call for a full-scale effort to tighten rhythm control therapy upstream and downstream, considering the major drivers of recurrent atrial fibrillation in patients by stratified therapy.

Funding
This work was partially supported by the European Union [grant agreement no. 633196 (CATCH ME) to P.K. and L.F.], the British Heart Foundation (FS/13/33/30324 to P.K. and L.F., PG/17/55/33087 to D.P.), and the Leducq Foundation to P.K.

Conflict of interest: P.K. receives additional research support from the Medical Research Council (UK), the German Centre for Cardiovascular Research, and from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies. P.K. and L.F. are listed as inventor on two patents held by the University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for and L.F. are listed as inventor on two patents held by the University of Birmingham, and has received honoraria from several such companies. P.K. receives additional research support from the University of Birmingham user.

References

